Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease

NCT02453607 is registered in ClinicalTrials.gov with Ernest Seidman as lead sponsor.

NCT NCT02453607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02453607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease
Lead sponsor
Ernest Seidman
Phase
Observational
Overall status
Unknown status
Start date
November 17, 2014
Completion date
June 30, 2020
Enrollment
225 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, inflammatory bowel disease